Fenwick & West represented GRAIL, Inc., a life sciences company whose mission is to detect cancer early when it can be cured, in its definitive agreement to combine with Cirina, Ltd., a privately held company based in Hong Kong that is also focused on the early detection of cancer.
The business combination will enhance GRAIL's ability to achieve its goal of reducing global cancer mortality through the early detection of cancer and will also expand GRAIL’s ability to develop and commercialize products in Asian and Western markets. More information about GRAIL’s definitive agreement to combine with Cirina can be obtained from the company press release.
The Fenwick transaction team was led by corporate lawyers Ken Myers, Matthew Rossiter, Jordan Koss, Holly Hoch, Elizabeth Federowicz and Kyle Canchola; executive compensation and employee benefits lawyers Shawn Lampron, Marshall Mort, Taylor Cashwell and Elizabeth Chang; technology transactions lawyers Jake Handy and Michael Shuster; tax lawyers Will Skinner and Sophia Huang; and antitrust lawyers Mark Ostrau and Ashley Walter.